# CDT Equity Inc.: overview CDT · Nasdaq · CIK 1896212 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cdt.md) · [Financials](/companies/cdt/financials.md) · [Filings](/companies/cdt/filings.md) · [Insiders](/companies/cdt/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(889.58)](/filings/0001493152-25-022373.md) | not reported | [(3670.27)](/filings/0001493152-26-033380.md) | [(10940.11)](/filings/0001493152-26-037458.md) | [(13.16)](/filings/0001493152-25-022373.md) | not reported | [(5.56)](/filings/0001493152-26-033380.md) | [(8.71)](/filings/0001493152-26-037458.md) | | Free cash flow | $k | [(2,040) d](/filings/0001493152-25-022373.md) | [(3,813) d](/filings/0001493152-26-016858.md) | [(4,333)](/filings/0001493152-26-033380.md) | [(2,581) d](/filings/0001493152-26-037458.md) | [(4,417) d](/filings/0001493152-25-022373.md) | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.13)](/filings/0001493152-24-014889.md) | [(8.92)](/filings/0001641172-25-001246.md) | [(61598.62)](/filings/0001493152-26-016858.md) | [(1177.89)](/filings/0001493152-26-016858.md) | | Free cash flow | $k | not reported | not reported | [(9,733)](/filings/0001493152-26-016858.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cdt/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-08-28 | [Regan Andrew](/insiders/1991325.md) | Chief Executive Officer, Director, Officer, 10% owner | Sale (S) | 29 | not reported | not reported | [Form 4/A](/filings/0001753926-26-002009.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $140.0k | 250,000 | | Unchanged | | [Polar Asset Management Partners Inc.](/funds/1326389.md) | 2026-06-30 | $13.9k | 950,000 | | Unchanged | | [Saba Capital Management, L.P.](/funds/1510281.md) | 2026-06-30 | $12.5k | 765,000 | | Unchanged | | [TORONTO DOMINION BANK](/funds/947263.md) | 2026-06-30 | $12.1k | 755,191 | | Reduced −200 | | [MMCAP International Inc. SPC](/funds/1304857.md) | 2026-06-30 | $11.5k | 700,000 | | Unchanged | | [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $8.8k | 534,162 | | Reduced −200 | | [Decagon Asset Management LLP](/funds/1950677.md) | 2026-06-30 | $6.6k | 400,000 | | Unchanged | | [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $4.1k | 375,000 | | Unchanged | | [WOLVERINE ASSET MANAGEMENT LLC](/funds/1279891.md) | 2026-06-30 | $4.0k | 243,532 | | Unchanged | | [RIVERNORTH CAPITAL MANAGEMENT, LLC](/funds/1447578.md) | 2026-06-30 | $2.4k | 200,000 | | Unchanged | ## Recent filings [All 365 filings](/companies/cdt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 16:58 ET | [DEF 14A](/filings/0001493152-26-048693.md) | Proxy statement, period 2026-10-27 | 0001493152-26-048693 | | 2026-10-27 | 16:28 ET | [SCHEDULE 13D/A](/filings/0001753926-26-002007.md) | Ownership report, active investor, amended | 0001753926-26-002007 | | 2026-10-27 | 08:15 ET | [8-K](/filings/0001493152-26-048638.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-048638 | | 2026-10-13 | 08:00 ET | [8-K](/filings/0001493152-26-046738.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-046738 | | 2026-09-25 | 08:15 ET | [8-K](/filings/0001493152-26-044248.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-044248 | | 2026-09-18 | 17:15 ET | [8-K](/filings/0001493152-26-043398.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-043398 | | 2026-09-08 | 17:30 ET | [S-1](/filings/0001493152-26-041808.md) | Registration statement | 0001493152-26-041808 | | 2026-09-04 | 16:05 ET | [8-K](/filings/0001493152-26-041533.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-041533 | | 2026-09-02 | 18:10 ET | [SCHEDULE 13D/A](/filings/0001753926-26-001696.md) | Ownership report, active investor, amended | 0001753926-26-001696 | | 2026-09-01 | 16:15 ET | [8-K](/filings/0001493152-26-041016.md) | 8.01 Other events | 0001493152-26-041016 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-016858.md), filed Apr 15, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1896212 - Tickers: CDT, CDTTW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:31 ET. No prices; not investment advice.